(Q44538505)

3 December 2017

title

Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer (English)

1 reference

3 December 2017

1 reference

Eduardo Batista Cândido

1

1 reference

3 December 2017

Luciana Maria Silva

2

1 reference

3 December 2017

Andréa Teixeira Carvalho

3

1 reference

3 December 2017

Rívia Mara Lamaita

4

1 reference

3 December 2017

Roberto Mundim Porto Filho

5

1 reference

3 December 2017

Bianca Della Croce Vieira Cota

6

1 reference

3 December 2017

Agnaldo Lopes da Silva-Filho

7

1 reference

3 December 2017

publication date

13 December 2012

1 reference

3 December 2017

published in

Reproductive Sciences

1 reference

3 December 2017

volume

20

1 reference

3 December 2017

issue

7

1 reference

3 December 2017

page(s)

828-837

1 reference

Cancer despite immunosurveillance: immunoselection and immunosubversion

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

The IL-4 receptor: signaling mechanisms and biologic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

The biological functions of T helper 17 cell effector cytokines in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Ovarian cancer screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Immunological profiling of a panel of human ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Altered immune responses in interleukin 10 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

Cytokine analysis as a tool to understand tumour–host interaction in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719112466299

21 January 2018

Identifiers

DOI

10.1177/1933719112466299

1 reference

3 December 2017

1 reference